NGL FINECHEM
Back to Cashflow Statement
|
NGL FINECHEM Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹30 Cr | ₹37 Cr | ₹-1.08 Cr | ₹-1.08 Cr | ₹-1.08 Cr |
What is the latest Cash Flow from Financing Activities ratio of NGL FINECHEM ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹30 Cr |
| Mar2025 | ₹37 Cr |
| Mar2024 | ₹-1.08 Cr |
| Mar2023 | ₹-1.08 Cr |
| Mar2022 | ₹-1.08 Cr |
How is Cash Flow from Financing Activities of NGL FINECHEM Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹30 Cr | -21.15 | |
| Mar2025 | ₹37 Cr | Positive | |
| Mar2024 | ₹-1.08 Cr | Negative | |
| Mar2023 | ₹-1.08 Cr | Negative | |
| Mar2022 | ₹-1.08 Cr | - | |
Compare Cash Flow from Financing Activities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,711.3 Cr | -3.9% | 1.9% | 82.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,684.0 Cr | -1.4% | -6.5% | 5.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,311.0 Cr | -2% | -2.7% | 40.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹173,079.0 Cr | -1.8% | -7% | 29.6% | Stock Analytics | |
| CIPLA | ₹107,528.0 Cr | 0.1% | -3% | -15.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,667.0 Cr | 0.2% | 6% | -2.4% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -3.9% |
1.9% |
82.3% |
| SENSEX | 2.7% |
-0.7% |
-10.5% |
You may also like the below Video Courses